Document Detail


Polyunsaturated fatty acids in the developing human brain, erythrocytes and plasma in peroxisomal disease: therapeutic implications.
MedLine Citation:
PMID:  9053556     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients with Zellweger syndrome and related peroxisomal disorders have profound changes in the polyunsaturated fatty acid (PUFA) patterns in brain and other tissues, with a constant decrease in docosahexaenoic acid (DHA, 22: 6omega3) concentration. Arachidonic acid (AA, 20: 4omega6) concentration is normal or increased and linoleic acid (LA, 18: 2omega6) is increased in the brain of Zellweger patients. In the retina of these patients, the levels of DHA are extremely low. Since these alterations are reflected elsewhere, they can be detected in vivo in patients with generalized peroxisomal disorders by measuring the PUFA content of plasma and erythrocytes, which show very low concentrations of DHA. The concentration of AA is low in plasma in generalized peroxisomal patients, although it is within normal limits in erythrocytes. Patients with X-linked adrenoleukodystrophy (X-ALD) or adrenomyeloneuropathy (AMN) have a normal DHA and AA content in both plasma and erythrocytes, unless they receive extremely low-PUFA diets. Given the probable role of DHA deficiency in the pathogenesis of Zellweger syndrome (ZS), it is important to normalize concentrations of DHA, at least in blood, in an attempt to correct the DHA deficiency in brain. DHA ethyl ester was given orally to two infants with a peroxisome deficiency disorder for a year, and some favourable biochemical changes were produced in erythrocytes and plasma. Normalization of the DHA concentrations in erythrocytes was obtained in about 2 months, and the ratios 26: 0/22: 0 and 26: 1/22: 0 decreased markedly in plasma in the two patients. The plasmalogen ratio 18: 0 dimethyl acetal/18: 0 in erythrocytes increased to virtually normal values in both patients. There was a clear clinical improvement in the two patients, which paralleled the increase in blood DHA. The concentrations of AA and other PUFAs were closely monitored and, when necessary, AA was added to the diet. Such a DHA therapy, given under close biochemical and clinical control, and accompanied by a diet rich in other long-chain PUFA, is strongly recommended in all patients with peroxisomal disorders in whom a DHA deficiency is detected in blood.
Authors:
M Martinez
Related Documents :
21435666 - Exogenous c3 postpones complement exhaustion and confers organ protection in murine sep...
8669956 - Factors affecting the variation in plasma phenylalanine in patients with phenylketonuri...
4083346 - Use of reciprocal pool specific activities to model leucine metabolism in humans.
16826496 - Low levels of environmental ammonia increase susceptibility to disease in chinook salmo...
22891006 - 1-α hydroxylation defect in postural orthostatic tachycardia syndrome: remission with c...
15275646 - Daily and annual variations of free fatty acid, glycerol and leptin plasma concentratio...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Journal of inherited metabolic disease     Volume:  18 Suppl 1     ISSN:  0141-8955     ISO Abbreviation:  J. Inherit. Metab. Dis.     Publication Date:  1995  
Date Detail:
Created Date:  1997-03-13     Completed Date:  1997-03-13     Revised Date:  2007-03-21    
Medline Journal Info:
Nlm Unique ID:  7910918     Medline TA:  J Inherit Metab Dis     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  61-75     Citation Subset:  IM    
Affiliation:
Biomedical Research Unit, Autonomous University of Barcelona, Maternity-Children Hospital, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Brain / growth & development
Brain Chemistry / physiology*
Child
Child, Preschool
Erythrocytes / metabolism*
Fatty Acids, Unsaturated / blood,  metabolism*
Female
Humans
Infant
Infant, Newborn
Peroxisomal Disorders / blood,  metabolism*,  therapy*
Pregnancy
Chemical
Reg. No./Substance:
0/Fatty Acids, Unsaturated

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pre- and postnatal diagnosis of peroxisomal disorders using stable-isotope dilution gas chromatograp...
Next Document:  Measurement of very long-chain fatty acids, phytanic and pristanic acid in plasma and cultured fibro...